D G Bostwick

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Staging prostate cancer--1997: current methods and limitations
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 32:2-14. 1997
  2. ncbi Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Anal Quant Cytol Histol 20:323-42. 1998
  3. ncbi Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention
    D G Bostwick
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn 55905, USA
    Eur Urol 35:492-5. 1999
  4. ncbi Evaluating radical prostatectomy specimens: therapeutic and prognostic importance
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Virchows Arch 430:1-16. 1997
  5. ncbi Extranodal extension in lymph node-positive prostate cancer
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Mod Pathol 13:113-8. 2000
  6. ncbi Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Cancer 85:2638-47. 1999
  7. ncbi Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Clin Cancer Res 5:2820-3. 1999
  8. ncbi Diagnosis of prostate cancer in needle biopsies after radiation therapy
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Am J Surg Pathol 23:1173-83. 1999
  9. ncbi Predictors of cancer progression in T1a prostate adenocarcinoma
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Cancer 85:1300-4. 1999
  10. ncbi Risk of prostate carcinoma death in patients with lymph node metastasis
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Cancer 91:66-73. 2001

Collaborators

Detail Information

Publications38

  1. ncbi Staging prostate cancer--1997: current methods and limitations
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 32:2-14. 1997
    ..Recent international agreement on the pathologic staging of prostate cancer should allow valid comparisons of surgical treatment from different institutions...
  2. ncbi Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Anal Quant Cytol Histol 20:323-42. 1998
    ....
  3. ncbi Reversibility of prostatic intraepithelial neoplasia: implications for chemoprevention
    D G Bostwick
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn 55905, USA
    Eur Urol 35:492-5. 1999
    ..Androgen deprivation therapy and radiation therapy decrease its prevalence and extent, suggesting a role in chemoprevention...
  4. ncbi Evaluating radical prostatectomy specimens: therapeutic and prognostic importance
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Virchows Arch 430:1-16. 1997
    ..Recent international agreement on pathologic staging of prostate cancer should allow valid comparisons of surgical treatment from different institutions. The vanishing cancer phenomenon is also briefly discussed...
  5. ncbi Extranodal extension in lymph node-positive prostate cancer
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Mod Pathol 13:113-8. 2000
    ..In contrast, nodal cancer volume was predictive of distant metastasis-free survival and cancer-specific survival...
  6. ncbi Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Cancer 85:2638-47. 1999
    ..Evidence has accumulated that cancers invading the superficial muscle wall (T2a) behave similarly to those invading the deep muscle wall (T2b). Quantitative analysis of the depth of invasion in relation to patient outcome is needed...
  7. ncbi Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Clin Cancer Res 5:2820-3. 1999
    ..52 and 0.17, respectively). Our data indicate that assessment of cell proliferation in nodal metastasis is predictive of clinical outcome in prostate cancer patients with regional lymph node metastasis...
  8. ncbi Diagnosis of prostate cancer in needle biopsies after radiation therapy
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Am J Surg Pathol 23:1173-83. 1999
    ..Conversely, Gleason grade in postirradiation needle biopsy specimens appeared to provide useful predictive information and should be reported...
  9. ncbi Predictors of cancer progression in T1a prostate adenocarcinoma
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Cancer 85:1300-4. 1999
    ..In the current study the authors attempted to identify such predictors of cancer progression in a large series of untreated patients with lengthy follow-up...
  10. ncbi Risk of prostate carcinoma death in patients with lymph node metastasis
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Cancer 91:66-73. 2001
    ..Results of published reports on survival among patients with lymph node metastasis are difficult to assess because of treatment selections. The extent to which lymph node status will have an impact on a patient's survival is uncertain...
  11. ncbi Mutation and expression analysis of the p73 gene in prostate cancer
    A Yokomizo
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Prostate 39:94-100. 1999
    ..Recently, p73, a first homologue of p53, was identified and considered to be an imprinted tumor suppressor gene. Thus, we analyzed the possible role of p73 in human prostate cancers...
  12. ncbi Paraganglioma of the urinary bladder: can biologic potential be predicted?
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer 88:844-52. 2000
    ..Paraganglioma of the urinary bladder is rarely encountered and its biologic behavior is uncertain. The authors sought to determine the prognostic factors that would predict patient outcome...
  13. ncbi The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Clin Cancer Res 6:1896-9. 2000
    ..06 and 0.01, respectively). These findings indicate that p21 and p27 expression levels are significant predictors of survival for patients selected for salvage prostatectomy for recurrent prostate cancer...
  14. ncbi Diagnosis and grading of bladder cancer and associated lesions
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Urol Clin North Am 26:493-507. 1999
    ..Uniformity of pathologic reporting should improve the comparability of different studies and therapies and provide more accurate information to urologists in managing patients...
  15. ncbi Predicting the survival of bladder carcinoma patients treated with radical cystectomy
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Cancer 88:2326-32. 2000
    ..Clinical outcomes vary for patients treated with radical cystectomy. The authors sought to identify factors associated with the survival of patients treated with radical cystectomy for urothelial carcinoma of the urinary bladder...
  16. ncbi Atypical nephrogenic metaplasia of the urinary tract: a precursor lesion?
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer 88:853-61. 2000
    ..Nephrogenic metaplasia with cytologic atypia (atypical nephrogenic metaplasia) is occasionally encountered and its biologic potential is uncertain...
  17. ncbi Predicting cancer progression in patients with stage T1 bladder carcinoma
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Clin Oncol 17:3182-7. 1999
    ..We sought to identify factors associated with cancer progression in a series of patients with stage T1 bladder carcinoma treated with a contemporary therapeutic approach...
  18. ncbi Urothelial papilloma of the bladder. Clinical and biologic implications
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Cancer 86:2098-101. 1999
    ..An international consensus has been reached regarding diagnostic criteria for papilloma of the urinary bladder. However, the incidences of recurrence and progression in patients with urothelial papilloma are uncertain...
  19. ncbi Natural history of urothelial dysplasia of the bladder
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Am J Surg Pathol 23:443-7. 1999
    ..The authors conclude that urothelial dysplasia is a significant risk for the development of CIS and invasive urothelial carcinoma, and patients with urothelial dysplasia should be followed up closely...
  20. ncbi Squamous papilloma of the urinary tract is unrelated to condyloma acuminata
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer 88:1679-86. 2000
    ..To the authors' knowledge, there is no previous report of squamous papilloma of the urinary tract. It is uncertain whether there is a correlation between squamous papilloma, condyloma acuminatum, and verrucous carcinoma...
  21. ncbi Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 30:145-52. 1996
    ..This report describes the diagnostic criteria for prostatic intraepithelial neoplasia, its clinical significance, and the evidence suggesting that it progresses to prostatic adenocarcinoma...
  22. ncbi Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer 88:1663-70. 2000
    ..Urothelial carcinoma of the bladder often contains areas with different histologic grades. The influence of cancer heterogeneity on grading and its relation to patient outcome is uncertain...
  23. ncbi Conserved genetic findings in metastatic bladder cancer: a possible utility of allelic loss of chromosomes 9p21 and 17p13 in diagnosis
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Arch Pathol Lab Med 125:1197-9. 2001
    ..Molecular analysis of microsatellite alterations of biologically distinct tumor cell subpopulations from the same patient may aid in the determination of tumor origin and further our understanding of the genetic basis of cancer progression...
  24. ncbi Molecular biology of prostatic intraepithelial neoplasia
    D G Bostwick
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Prostate 29:117-34. 1996
    ..Further studies are needed to evaluate the function and prognostic value of oncogene expression in the normal, preneoplastic, and neoplastic prostate...
  25. ncbi Expression of early growth response genes in human prostate cancer
    M A Eid
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 58:2461-8. 1998
    ..These results show that EGR-1 is overexpressed in prostate cancer and suggest a role for EGR-1 in prostate cancer growth...
  26. ncbi Steam heat with an EDTA buffer and protease digestion optimizes immunohistochemical expression of basal cell-specific antikeratin 34betaE12 to discriminate cancer in prostatic epithelium
    K A Iczkowski
    Department of Pathology, Mayo Clinic Rochester, Minnesota 55905, USA
    Mod Pathol 12:1-4. 1999
    ..This helps to prevent misinterpretation of histologic mimics of cancer, such as atrophic acini and high-grade prostatic intraepithelial neoplasia, that result from false-negative staining...
  27. ncbi Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation
    K A Iczkowski
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Arch Pathol Lab Med 124:98-107. 2000
    ..We previously described the diagnostic category called atypical small acinar proliferation (ASAP), suspicious for but not diagnostic of malignancy, present in about 2.5% of routine prostatic needle biopsy specimens...
  28. ncbi Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas
    L Cheng
    Department of Pathology, Indiana University School of Medicine, Indianapolis 46202, USA
    Am J Surg Pathol 25:1231-6. 2001
    ..The coexistence of tumor subclones with morphologic heterogeneity can lead to the formation of a clinically detectable tumor...
  29. ncbi Human acid ceramidase is overexpressed but not mutated in prostate cancer
    R S Seelan
    Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
    Genes Chromosomes Cancer 29:137-46. 2000
    ..These results suggest that acid ceramidase may play an important role in prostate carcinogenesis...
  30. ncbi Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Urol Clin North Am 26:465-79. 1999
    ..Pathologists must be aware of these distinct changes because of the reliance placed on nuclear and nucleolar size in the identification of prostate cancer, particularly in small specimens and lymph node metastases...
  31. ncbi High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer
    J W Aquilina
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Prostate 36:189-93. 1998
    ..This method will provide important data to determine whether a model of spontaneous PIN in elderly dogs may have clinical utility in developing strategies directed toward preventing and treating prostate...
  32. ncbi Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4
    W K Lau
    Department of Urology, Laboratory Medicine and Pathology, Section of Biostatistics, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 166:1692-7. 2001
    ..However, primary Gleason grade does not provide any additional information than other known prognostic factors, such as preoperative PSA, seminal vesicle invasion and DNA ploidy...
  33. ncbi Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker
    M F Darson
    Department of Urology, Mayo Clinic, Rochester, MN 35905, USA
    Urology 49:857-62. 1997
    ..We describe the expression of a potentially new tumor marker, human glandular kallikrein 2 (hK2), that may be useful as an adjunct to prostate-specific antigen (PSA) in the diagnosis and monitoring of prostate cancer...
  34. ncbi Diagnosis and classification of renal cell carcinoma
    D G Bostwick
    Department of Pathology, Mayo Clinic, Rochester, Minnesota, USA
    Urol Clin North Am 26:627-35. 1999
    ....
  35. ncbi Prostatic intraepithelial neoplasia (PIN): current concepts
    D G Bostwick
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905
    J Cell Biochem Suppl 16:10-9. 1992
    ..The clinical importance of recognizing PIN is based on its strong association with carcinoma; its identification in biopsy specimens of the prostate warrants further search for concurrent invasive carcinoma...
  36. ncbi Workgroup I: rodent models of prostate cancer
    M S Lucia
    Department of Pathology, University of Colorado, Denver, USA
    Prostate 36:49-55. 1998
  37. ncbi Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis
    J Jiang
    Department of Pathology, Indiana University School of Medicine, Indianapolis, Ind. 46202, USA
    Arch Pathol Lab Med 125:921-3. 2001
    ..All cases showed positive CK7 immunoreactivity in the primary cancers and matched lymph node metastases. CONCLUSIONS:-CK20 immunoreactivity is reliably observed in metastases from bladder cancer when the primary tumor expresses CK20...
  38. ncbi Overexpression of the wild type p73 gene in human bladder cancer
    A Yokomizo
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55095, USA
    Oncogene 18:1629-33. 1999
    ..These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer...